Veramyst
(Fluticasone furoate)PreclinicalSmall molecule
GSKFluticasone furoate is an inhaled steroid used to prevent asthma attacks and reduce inflammation in the airways. It's also used as a nasal spray to relieve allergy symptoms like congestion and sneezing.[1] Veramyst is currently being investigated across 6 indications[3], with its most advanced program in Preclinical.[1]
Veramyst is one of 117 small molecule programs targeting Emphysema. It is currently in Preclinical.
6
Indications
134
Total Trials
0
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Cognition
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaApproved
Pitocin
RRetrophin
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Namenda
AbbViePhase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 2
Remimazolam Tosilate
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Psilocybin
COMPASS PathwaysPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma46 trials
Show 43 more trials
Chronic Obstructive Pulmonary Disease26 trials
Show 23 more trials
Allergic Rhinitis10 trials
Show 7 more trials
Efficacy and Safety4 trials
27 more indications
Salmeterol3 trials
Acute Lymphoblastic Leukemia3 trials
Treatment2 trials
Oral2 trials
Tics2 trials
Intravenous2 trials
MPA2 trials
Allergy2 trials
Seasonal Allergic Rhinitis2 trials
Polyp1 trial
Arterial Stiffness1 trial
LAM1 trial
Drug1 trial
Airway Disease1 trial
Corticosteroids1 trial
Inflammation1 trial
Cardiovascular Disease1 trial
Outcome1 trial
Obstructive Sleep Apnea1 trial
Chronic Rhinosinusitis With Nasal Polyps1 trial
Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.
Unknown status·—·Phase 1/2·NCT05143502·60 enrolled
Unspecified8 trials
Show 5 more trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluticasone furoate. EMBL-EBI & Wellcome Sanger Institute.
- [4]